85 related articles for article (PubMed ID: 22745924)
21. Ipilimumab for metastatic melanoma.
Ozao-Choy J; Carvajal RD; Hamid O
Drugs Today (Barc); 2012 Jun; 48(6):381-93. PubMed ID: 22745924
[TBL] [Abstract][Full Text] [Related]
22. Ipilimumab in the treatment of melanoma.
Trinh VA; Hwu WJ
Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
[TBL] [Abstract][Full Text] [Related]
23. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
[TBL] [Abstract][Full Text] [Related]
24. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
26. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
Maio M; Di Giacomo AM; Robert C; Eggermont AM
Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
[TBL] [Abstract][Full Text] [Related]
27. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Patel SP; Woodman SE
Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
[TBL] [Abstract][Full Text] [Related]
28. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
Eggermont AM; Maio M; Robert C
Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
[TBL] [Abstract][Full Text] [Related]
30. Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma.
Peggs KS; Quezada SA
Expert Rev Anticancer Ther; 2010 Nov; 10(11):1697-701. PubMed ID: 21080797
[TBL] [Abstract][Full Text] [Related]
31. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Wolchok JD; Hodi FS; Weber JS; Allison JP; Urba WJ; Robert C; O'Day SJ; Hoos A; Humphrey R; Berman DM; Lonberg N; Korman AJ
Ann N Y Acad Sci; 2013 Jul; 1291(1):1-13. PubMed ID: 23772560
[TBL] [Abstract][Full Text] [Related]
32. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
33. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
Savoia P; Astrua C; Fava P
Hum Vaccin Immunother; 2016 May; 12(5):1092-101. PubMed ID: 26889818
[TBL] [Abstract][Full Text] [Related]
34. Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.
Wang XY; Zuo D; Sarkar D; Fisher PB
Expert Opin Pharmacother; 2011 Dec; 12(17):2695-706. PubMed ID: 22077831
[TBL] [Abstract][Full Text] [Related]
35. [Unblocking antitumor immune response: novel possibilities for the immunotherapy of melanoma].
Ladányi A; Balatoni T
Magy Onkol; 2013 Jun; 57(2):100-7. PubMed ID: 23795355
[TBL] [Abstract][Full Text] [Related]
36. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
[TBL] [Abstract][Full Text] [Related]
38. Immunomodulatory therapy for melanoma: ipilimumab and beyond.
Callahan MK; Postow MA; Wolchok JD
Clin Dermatol; 2013; 31(2):191-9. PubMed ID: 23438382
[TBL] [Abstract][Full Text] [Related]
39. Ipilimumab: a promising immunotherapy for melanoma.
Thumar JR; Kluger HM
Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
